Overview

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborators:

Eastern Hepatobiliary Surgery Hospital
Huashan Hospital
RenJi Hospital
Ruijin Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Cetuximab
Crizotinib
Everolimus
Gefitinib
Lapatinib
Sorafenib
Trastuzumab